Cardiovascular diseases (myocardial infarction, cerebral ischemia, or lower-limb arterial disease) contribute significantly to mortality and morbidity in our societies. These diseases are the result of arterial obstruction that consequently reduces the blood supply to the heart or to the peripheral tissues. This results in ischemia or necrosis of the tissue in question. New therapeutic approaches must therefore be developed to treat these diseases. The idea of promoting vascularization in tissues that suffer from a lack of blood supply, as is the case in myocardial infarction, stroke, and lower-limb arterial disease, is a sound strategy. The idea was to promote collateral circulation to save poorly irrigated tissue that suffers from a lack of oxygen supply (“ischemic tissue”). In the chapter on the history of angiogenesis we saw that John Hunter had already somehow anticipated this idea.
- 142.Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, Pilsudski R (2002) Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35(5):930–936CrossRefPubMedGoogle Scholar
- 143.Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH, Investigators T (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359(9323):2053–2058CrossRefPubMedGoogle Scholar
- 146.Rohde E, Schallmoser K, Reinisch A, Hofmann NA, Pfeifer T, Frohlich E, Rechberger G, Lanzer G, Kratky D, Strunk D (2011) Pro-angiogenic induction of myeloid cells for therapeutic angiogenesis can induce mitogen-activated protein kinase p38-dependent foam cell formation. Cytotherapy 13(4):503–512. https://doi.org/10.3109/14653249.2010.536214CrossRefPubMedGoogle Scholar